Genitourinary cancers include prostate, bladder, kidney, and testicular cancers, with diagnosis involving imaging and biopsy. Treatment is personalized, involving surgery, radiation, chemotherapy, ...

Fotivda monotherapy may match or outperform combination therapy in metastatic renal cell carcinoma, offering comparable progression-free survival and objective response rates. The 2025 ASCO Annual ...

Donna Hansel, MD, PhD, of University of California, San Diego, School of Medicine, explains her use of human bladder cancer cells in her research. Having numerous therapies to treat prostate cancer ...

Real-world evidence shows Pluvicto matches pivotal trial benefits in PSMA-positive mCRPC, with longer PFS after an androgen receptor pathway inhibitor. Tanya B. Dorff, MD, medical oncologist and ...

CYP2D6 poor metabolizers had ~5-fold higher payload exposure and excess grade ≥3 mucositis, neutropenia, febrile neutropenia, ...

For aging men, worrying about prostate health can start to feel like a real … well, you know. But as Dr. Leonard Appleman of ...

More than 20 abstracts span Pfizer’s leading genitourinary cancer portfolio of approved standards of care and growing pipeline across prostate and bladder cancers Detailed overall survival (OS) ...

Toni K. Choueiri, MD, director of the Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute, presents findings from the phase 3 LITESPARK-022 study at the 2026 American Society of ...

Late-breaking KEYNOTE-B15 data show KEYTRUDA® (pembrolizumab) plus Padcev® (enfortumab vedotin-ejfv) significantly improved event-free survival, overall survival and pathologic complete response rates ...

The HUGO robotic-assisted surgery system showed a high surgical success rate and favorable rates of grade 3 complications. The Hugo™ robotic-assisted surgery (RAS) system is safe and effective, ...

This study validated PROSTOX as predicting radiotherapy-induced genitourinary toxicity, which can be differentiated into acute and chronic with mirSNP-based signatures, in patients with prostate ...

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) will present the latest results from its leading genitourinary (GU) portfolio at the American Society of Clinical Oncology Genitourinary (ASCO GU) ...